



Antibacterial activity of *Trigona* sp. propolis extract against *Aggregatibacter actinomycetemcomitans* in vitro

Yuni^{1,2*}, Sumitro^{1,2}, Angelin Nehemia Juniarti Butarbutar³, Linda Novelgia Setiawan¹, Shirley Adriana¹, Bella Fernanda¹

ABSTRACT

Background: *Aggregatibacter actinomycetemcomitans* is a primary pathogen in aggressive periodontitis. Plaque control uses chemical and natural agents. Propolis inhibits growth of bacteria, viruses, and fungi. This study assessed the in vitro antibacterial activity of *Trigona* sp. propolis extract against *A. actinomycetemcomitans*.

Methods: This true experimental laboratory study used a post-test-only control group design. Samples were *A. actinomycetemcomitans* bacteria in 8 groups (n=5 each). The dilution method tested antibacterial activity. Data analysis used Kruskal-Wallis and Mann-Whitney tests.

Results: Mean *A. actinomycetemcomitans* colony counts (mean \pm SD) were 5.60 ± 1.52 , 11.60 ± 4.83 , 15.60 ± 5.03 , 22.20 ± 2.86 , 25.40 ± 6.43 , and 141.80 ± 5.40 for propolis concentrations of 50, 25, 12.5, 6.25, 3.125, and 1.56, respectively. Negative control (DMSO) showed uncountable colonies; positive control (chlorhexidine) showed none. Kruskal-Wallis test indicated significant differences ($p=0.001$). Mann-Whitney test showed differences between most groups ($p<0.05$), except 25 vs. 12.5% ($p=0.421$), 12.5 vs. 3.125% ($p=0.056$), and 6.25 vs. 3.125% ($p=0.151$).

Conclusion: *Trigona* sp. propolis inhibited and showed bactericidal potential against *A. actinomycetemcomitans* in vitro, with minimum inhibitory concentration at 3.125% and minimum bactericidal concentration at 50%.

Keywords: MIC, MBC, *Aggregatibacter actinomycetemcomitans*, *Trigona* sp. propolis

Introduction

In 2018, the Indonesian Basic Health Research (RISKESDAS) reported that 57.6% of the Indonesian population had oral and dental health problems; dental caries had the highest prevalence at 88.8%, followed by periodontal disease at 74.1%.¹ The high prevalence of periodontal disease is associated with low oral hygiene awareness, infrequent dental visits, low socioeconomic status, and high illiteracy rates.^{2,3} Periodontitis is an inflammatory disease that affects the tooth-supporting structures; it is caused by specific microorganisms and results in progressive destruction of the periodontal ligament and alveolar bone, as well as periodontal pocket formation or gingival recession.⁴ The American Academy of Periodontology classifies periodontal disease into chronic periodontitis, aggressive periodontitis, and periodontitis as a manifestation of systemic diseases.⁵ Specific gram-negative microorganisms in dental plaque biofilm, such as *A. actinomycetemcomitans*, *Porphyromonas gingivalis*, *Prevotella intermedia*, and *Fusobacterium nucleatum*, contribute to periodontitis development.^{6,7}

Affiliation

¹Department of Dental Science, Universitas Prima Indonesia

²Center of Excellence for Phyto Degenerative & Lifestyle Medicine, Universitas Prima Indonesia

³Undergraduate Program in Dental Science, Universitas Prima Indonesia

*Correspondence:

yunioey85@gmail.com

Aggregatibacter actinomycetemcomitans (Aa) is a primary pathogen associated with aggressive periodontitis. This gram-negative, nonmotile, facultative anaerobic short rod induces progressive destruction of periodontal tissues.⁸ Periodontal therapy aims to restore the balance between the host and plaque bacteria through mechanical and chemical plaque control, including antiseptic mouthwashes such as chlorhexidine.^{9,10} Although chlorhexidine is the gold standard antimicrobial agent in dentistry, long-term use can cause adverse effects, including taste alteration, tooth and mucosal staining, and IgE- and histamine-mediated allergic reactions. These effects encourage the search for safer natural alternatives.¹¹⁻¹³

One potential natural antimicrobial agent is propolis, a resinous substance that bees collect from plant sources. It consists mainly of flavonoids and phenolic compounds, which have anti-inflammatory, antiviral, antifungal, and antibacterial properties.¹⁴⁻¹⁶ In Indonesia, propolis from *Trigona* sp. (stingless bees) is widely cultivated because of its easier maintenance and lack of a stinger.^{17,18} Flavonoids are the most active components in propolis and comprise approximately 50% of its content. They function as antibacterial agents by inhibiting nucleic acid synthesis, disrupting cell membrane integrity, and suppressing bacterial energy metabolism.¹⁹ Several studies have demonstrated the therapeutic potential of propolis in periodontal treatment. For example, propolis paste application led to clinical improvement in 90% of chronic periodontitis cases after one week.^{20,21} Propolis flavonoid extracts inhibit the growth of *A. actinomycetemcomitans* and *P. gingivalis*.²²

This study evaluated the *in vitro* antibacterial activity of *Trigona* sp. propolis extract against *Aggregatibacter actinomycetemcomitans* by determining minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values. The hypothesis stated that the extract exhibits inhibitory and bactericidal activity against *A. actinomycetemcomitans*.

Method

This study is a true experimental laboratory study using a posttest-only control group design to analyze the *in vitro* antibacterial activity of *Trigona* sp. propolis extract against *Aggregatibacter actinomycetemcomitans*. The study was conducted from August to September 2025. Propolis extract concentrations were prepared at the Laboratory for Research and Development of Medicinal Plants, whereas phytochemical testing, bacterial cultivation, and antibacterial testing were performed at the Integrated Laboratory, Universitas Prima Indonesia.

The samples included pure cultures of *A. actinomycetemcomitans* from an e-commerce supplier and *Trigona* sp. propolis extract from a honey beekeeper. Samples were assigned to eight groups: six propolis extract concentrations (1.56%, 3.125%, 6.25%, 12.5%, 25%, and 50%), one positive control (chlorhexidine), and one negative control (DMSO).

The independent variable was *Trigona* sp. propolis extract concentration. The dependent variable was bacterial growth, assessed by colony counts to determine minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). Controlled variables were Brain Heart Infusion (BHI) medium and 24-hour incubation. Equipment included a Buchner funnel, electric scale, blender, Erlenmeyer flask, rotary evaporator, test tubes, sterile inoculating loop, measuring pipette, water bath, Petri dishes, incubator, and electric stove. Materials were propolis extract, *A. actinomycetemcomitans* culture, 96% ethanol, BHI medium, Tryptic Soy Agar (TSA) medium, DMSO, aluminum foil, and chlorhexidine.

Propolis was extracted by maceration in 96% ethanol for 5 days, following a modified method from Firdaus et al. (2023). In total, 500 g of propolis was blended, soaked in ethanol with periodic stirring, filtered, and concentrated using a rotary evaporator and water bath to yield a viscous extract. The extract was diluted in DMSO to concentrations of 1.56%, 3.125%, 6.25%, 12.5%, 25%, and 50%. Phytochemical analysis identified alkaloids, flavonoids, saponins, and tannins, using a modified method from Kurniawati et al.²³

A. actinomycetemcomitans was subcultured on BHI medium and incubated at 37°C for 24 hours, then adjusted to 10⁸ CFU/mL per the McFarland standard. Antibacterial assays used tube dilution: each tube contained 1 mL bacterial suspension and 1 mL extract (per concentration), followed by 37°C incubation for 24 hours. MIC was assessed by medium turbidity; MBC was determined by streaking on TSA and checking colony growth.

Data underwent normality and homogeneity testing with the Shapiro-Wilk test. As data were not normally distributed and homogeneity assumptions were unmet, the Kruskal-Wallis test was followed by the Mann-Whitney U test. Analysis used SPSS version 25 for Windows.

Results

Visual observation revealed turbidity in all dilution tubes containing *Trigona* sp. propolis extract at concentrations of 50%, 25%, 12.5%, 6.25%, 3.125%, and 1.56%. This turbidity resulted from the dark color and viscosity of the extract, particularly at higher concentrations, which prevented direct determination of the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC).



Figure 1. Turbidity levels of dilution tubes in all groups

The positive control (chlorhexidine) tube was clear, confirming its inhibition of *A. actinomycetemcomitans* growth, whereas the negative control (DMSO) tube was turbid, indicating no antibacterial activity from DMSO alone. Turbidity assessment provided an initial step for MIC and MBC evaluation.

Table 1. Turbidity of *A. actinomycetemcomitans* after treatment with various concentrations of *Trigona* sp. propolis

Group	Replication I	Replication II	Replication III
DMSO	Turbid	Turbid	Turbid
K+	Clear	Clear	Clear
50%	Turbid	Turbid	Turbid
25%	Turbid	Turbid	Turbid
12.5%	Turbid	Turbid	Turbid
6.25%	Turbid	Turbid	Turbid
3.12%	Turbid	Turbid	Turbid
1.56%	Turbid	Turbid	Turbid

Mean colony counts of *A. actinomycetemcomitans* increased as *Trigona* sp. propolis concentration decreased. Counts at 50%, 25%, 12.5%, 6.25%, 3.125%, and 1.56% were 5.60 ± 1.52 , 11.60 ± 4.83 , 15.60 ± 5.03 , 22.20 ± 2.86 , 25.40 ± 6.43 , and 141.80 ± 5.40 , respectively. The positive control (chlorhexidine) showed no growth (mean = 0), while the negative control (DMSO) had uncountable colonies, excluded from mean and standard deviation calculations.

Shapiro-Wilk normality testing yielded $p < 0.05$ for 50% ($p = 0.044$), 25% ($p = 0.043$), and 3.12% ($p = 0.004$) groups, indicating non-normal distribution. Groups at 12.5% ($p = 0.298$), 6.25% ($p = 0.087$), and 1.56% ($p = 0.633$) had $p > 0.05$, indicating normal distribution. Levene's homogeneity test showed $p = 0.090$ (> 0.05), confirming homogeneous variances across groups.

Table 2. Normality and homogeneity test results

Group	Shapiro-Wilk p-value	Levene's p-value
DMSO	-	
K+	-	
50%	0.044	
25%	0.043	
12.5%	0.298	0.090
6.25%	0.087	
3.12%	0.004	
1.56%	0.633	

The Kruskal-Wallis test indicated significant differences in mean *A. actinomycetemcomitans* colony counts among groups ($p = 0.001$; $p < 0.05$). This supports the inhibitory and bactericidal potential of *Trigona* sp. propolis extract against *A. actinomycetemcomitans* in vitro.

Table 3. Mean *A. actinomycetemcomitans* colony counts among groups

Group	I	II	III	IV	V	$\bar{x} \pm SD$	p-value
DMSO	TNTC	TNTC	TNTC			-	-
K+	0	0	0	0	0	0	
50%	6	7	6	3	6	5.60 ± 1.52	
25%	9	8	10	20	11	11.60 ± 4.83	0.001*
12.5%	19	20	18	13	8	15.60 ± 5.03	
6.25%	22	22	20	27	20	22.20 ± 2.86	
3.12%	29	27	28	14	29	25.40 ± 6.43	
1.56%	142	135	140	142	150	141.80 ± 5.40	

(TNTC = too numerous to count)

Mann-Whitney U testing showed significant differences ($p < 0.05$) in colony counts for most group pairs. Non-significant differences occurred between 25% and 12.5% ($p = 0.421$), 12.5% and 3.125% ($p = 0.056$), and 6.25% and 3.125% ($p = 0.151$).

Table 4. Mann-Whitney U test p-values between groups

Groups	K+	50%	25%	12.5%	6.25%	3.125%
K+	-	0.008*	0.008*	0.008*	0.008*	0.008*
50%		-	0.008*	0.008*	0.008*	0.008*
25%			-	0.421	0.016*	0.016*
12.5%				-	0.016*	0.056
6.25%					-	0.151
3.125%						-
1.56%	0.008*	0.008*	0.008*	0.008*	0.008*	0.008*

Discussion

In this study, *Trigona* sp. propolis extract served as the test agent to evaluate its antibacterial activity against *Aggregatibacter actinomycetemcomitans* (Aa). *Trigona* sp. propolis, widely produced in Indonesia, has a favorable safety profile, including biocompatibility with human tissues, low toxicity, and low hypersensitivity incidence, supporting its use in health applications.²⁴ *Trigona* sp. propolis contains bioactive compounds with antibacterial, antifungal, antiviral, anti-inflammatory, antioxidant, and anticancer activities. These properties position it as a candidate for alternative antibacterial therapies.²⁵ Phytochemical screening identified secondary metabolites in the propolis extract, including alkaloids, tannins, flavonoids, and saponins, which contribute to its biological activities. These results align with reports by Kabani et al.²⁶ and Tukan et al.²⁷ of alkaloids, flavonoids, phenolic compounds, and tannins in *Trigona* sp. propolis.

Aggregatibacter actinomycetemcomitans, a Gram-negative bacterium associated with aggressive periodontitis, disrupts osteoblast activity and bone remodeling, promoting alveolar bone resorption.²⁸ Diffusion methods (disc or well) measure inhibition zones but yield inaccurate results with viscous extracts like propolis, as they preclude quantitative assessment. The dilution method was thus selected for its precision in determining minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values against *A. actinomycetemcomitans*.^{29,30}

Broth dilution turbidity was obscured by the extract's dark color at all concentrations (50%, 25%, 12.5%, 6.25%, 3.125%, 1.56%), preventing visual MIC and MBC determination. Agar dilution with colony counting confirmed activity: mean *A. actinomycetemcomitans* colony counts were 5.60 ± 1.52 , 11.60 ± 4.83 , 15.60 ± 5.03 , 22.20 ± 2.86 , 25.40 ± 6.43 , and 141.80 ± 5.40 , respectively. The MIC was 3.125%; MBC exceeded 50%, indicating dose-dependent inhibition.^{29,31} At 1.56%, colony counts remained high due to insufficient active compounds for cell wall or membrane disruption. *A. actinomycetemcomitans*' lipopolysaccharide-rich outer membrane further limits low-concentration efficacy. At 3.125% (MIC), colony counts decreased via bacteriostatic effects, with growth persisting up to 50%, confirming $MBC > 50\%$.²⁹

Antibacterial efficacy depends on bacterial characteristics, bioactive composition (varying by bee species, resin sources, environment), and methods (extraction, solvents, inoculum density, incubation). *A. actinomycetemcomitans*' outer membrane reduces compound penetration. Wulandari et al.³² reported MBC of 10% (100 mg/mL) against *Pseudomonas aeruginosa* and *Staphylococcus aureus*. Results align with Sinaga et al.³³ showing greater propolis activity against Gram-negative than Gram-positive bacteria due to lipopolysaccharide interference. Gram-negative cell walls feature thin peptidoglycan surrounded by lipoproteins, lipopolysaccharides, and phospholipids, impeding small molecules.²⁹

Kruskal-Wallis testing showed significant colony count differences across groups ($p < 0.05$), suitable for non-normal data with >2 groups. This supports Hidayat et al.³⁴ on *Trigona* spp. propolis against *Staphylococcus aureus* and Maghfiroh³⁵ on fungicidal effects against *Candida albicans*. Flavonoids disrupt membranes, reduce fluidity, cause leakage, ATP depletion, metabolic inhibition, and lysis.³⁵ Alkaloids inhibit peptidoglycan synthesis; tannins increase wall instability; saponins compromise integrity, promoting leakage and lysis.^{27,32} Mann-Whitney U testing confirmed significant differences between propolis concentrations and chlorhexidine positive control, appropriate for non-normal data.³⁶

Dimethyl sulfoxide (DMSO) dissolved propolis as negative control, showing no activity and confirming effects from propolis compounds. Chlorhexidine, the oral hygiene standard, acts via electrostatic binding, membrane disruption, leakage, and lysis but risks discoloration, taste changes, irritation, and resistance with prolonged use. This highlights the value of alternatives like *Trigona* sp. Propolis.^{36,37}

Conclusion

The results of this study demonstrate that *Trigona* sp. propolis extract exhibits in vitro antibacterial activity against *Aggregatibacter actinomycetemcomitans*, as indicated by a reduction in bacterial colony counts with increasing extract concentrations. The minimum inhibitory concentration (MIC) of *Trigona* sp. propolis extract was determined to be 3.125%, whereas the minimum bactericidal concentration (MBC) was greater than 50%.

References

1. Kementerian Kesehatan Republik Indonesia. Riset Kesehatan Dasar 2018 (2018 Basic Health Research). Jakarta; 2018.
2. Mahmud DS, Emon DKE, Sarmin DS, Hossin DMI, Rahman DM, Faruk DA al, et al. Prevalence of Common Dental Problems and Oral Hygiene Behaviors Among Adults in Bangladesh- A Cross-Sectional Study. *Sch J Dent Sci*. 2025 Jul 16;12(06):94–100.
3. Nazir MA. Prevalence of periodontal disease, its association with systemic diseases and prevention. *Int J Health Sci (Qassim)*. 2017;11(2):72–80.
4. Saini R, Marawar P, Shete S, Saini S. Periodontitis, a true infection. *J Glob Infect Dis*. 2009;1(2):149.
5. Caton JG, Armitage G, Berglundh T, Chapple ILC, Jepsen S, Kornman KS, et al. A new classification scheme for periodontal and peri-implant diseases and conditions – Introduction and key changes from the 1999 classification. *J Periodontol*. 2018 Jun 21;89(S1).
6. Yusoff ME, Hamdan DRH, Taib PMDH, Li Peng DT, Mohamed PDM, Shaari PMDR. Overview of Gram-negative anaerobic pathogens associated with periodontal disease: A review. *Asian J Med Biomed*. 2024 Oct 28;8(2):98–110.
7. Niazi P, Hejran AB, Saken K. The influence of gram-negative bacteria on oral health: A mini review. *Int J Med Sci Dent Heal*. 2024 Dec 11;10(12):30–51.
8. Fine DH, Patil AG, Velusamy SK. *Aggregatibacter actinomycetemcomitans* (Aa) Under the Radar: Myths and Misunderstandings of Aa and Its Role in Aggressive Periodontitis. *Front Immunol*. 2019 Apr 16;10.
9. Figuero E, Nóbrega DF, García-Gargallo M, Tenuta LMA, Herrera D, Carvalho JC. Mechanical and chemical plaque control in the simultaneous management of gingivitis and caries: a systematic review. *J Clin Periodontol*. 2017 Mar 6;44(S18).
10. James P, Worthington H V, Parnell C, Harding M, Lamont T, Cheung A, et al. Chlorhexidine mouthrinse as an adjunctive treatment for gingival health. *Cochrane Database Syst Rev*. 2017 Mar 31;2021(12).
11. Poppo Deus F, Ouanounou A. Chlorhexidine in Dentistry: Pharmacology, Uses, and Adverse Effects. *Int Dent J*. 2022 Jun;72(3):269–77.
12. Zanatta FB, Antoniazzi RP, Rösing CK. Staining and calculus formation after 0.12% chlorhexidine rinses in plaque-free and plaque covered surfaces: a randomized trial. *J Appl Oral Sci*. 2010 Oct;18(5):515–21.
13. Garvey LH, Krøigaard M, Poulsen LK, Skov PS, Mosbech H, Venemalm L, et al. IgE-mediated allergy to chlorhexidine. *J Allergy Clin Immunol*. 2007 Aug;120(2):409–15.
14. Nichitoi MM, Josceanu AM, Isopescu RD, Isopencu GO, Geana EI, Ciucure CT, et al. Polyphenolics profile effects upon the antioxidant and antimicrobial activity of propolis extracts. *Sci Rep*. 2021 Oct 11;11(1):20113.
15. Bouchelaghem S. Propolis characterization and antimicrobial activities against *Staphylococcus aureus* and *Candida albicans*: A review. *Saudi J Biol Sci*. 2022 Apr;29(4):1936–46.
16. Syed Salleh SNA, Mohd Hanapiah NA, Ahmad H, Wan Johari WL, Osman NH, Mamat MR. Determination of Total Phenolics, Flavonoids, and Antioxidant Activity and GC-MS Analysis of Malaysian Stingless Bee Propolis Water Extracts. Hanssen SA, editor. *Scientifica* (Cairo). 2021 Oct 22;2021:1–11.
17. Yanti EN, Kustiawan PM. Study of Indonesian Stingless Bee Propolis Potential as Antioxidant: A Review. *J Farm Sains dan Prakt*. 2023 Dec 29;9(3):261–9.
18. Febriani E, Pujiastuti Y. The stingless bee species *Trigona* spp. on various species of flowering plants in Baturaja City, Ogan Komering Ulu District, South Sumatra. *J Smart Agric Environ Technol*. 2023 Apr 30;1(1):7–13.
19. Farhadi F, Khameneh B, Iranshahi M, Iranshahi M. Antibacterial activity of flavonoids and their structure–activity relationship: An update review. *Phyther Res*. 2019 Jan 22;33(1):13–40.
20. Fraire-Reyes IA, Gaitán-Fonseca C, Cepeda-Argüelles Ó, Esparza-Villalpando V, Aguilera-Galaviz L, Bermúdez-Jiménez C. Use and Effectiveness of Propolis on Chronic Periodontitis: a Systematic Review. *Odvotos - Int J Dent Sci*. 2021 Oct 1;24(1):160–71.

21. Lisbona-González MJ, Muñoz-Soto E, Lisbona-González C, Vallecillo-Rivas M, Diaz-Castro J, Moreno-Fernandez J. Effect of Propolis Paste and Mouthwash Formulation on Healing after Teeth Extraction in Periodontal Disease. *Plants*. 2021 Aug 4;10(8):1603.
22. Agarwal G, Vemanaradhya GG, Mehta DS. Evaluation of chemical composition and efficacy of Chinese propolis extract on *Porphyromonas gingivalis* and *Aggregatibacter actinomycetemcomitans*: An in vitro study. *Contemp Clin Dent*. 2012 Jul;3(3):256–61.
23. Kurniawati E, Lestari TP, Hardini PH. Perbedaan kadar tanin total ekstrak daun turi (*Sesbania grandiflora* L.) varietas merah dan putih dengan metode spektrofotometri UV-VIS. *J Ris Kefarmasian Indones*. 2024 May 30;6(2):329–43.
24. Sabir A. Aktivitas antibakteri flavonoid propolis *Trigona* sp terhadap bakteri *Streptococcus mutans* (in vitro) (In vitro antibacterial activity of flavonoids *Trigona* sp propolis against *Streptococcus mutans*). *Dent J*. 2005 Sep 1;38(3):135.
25. Suryono S, Yassa RM, Saputro LT, Walianto AP, Seno Aji NRA. Antibacterial potential from periodontal dressing raw propolis *Trigona* itama bee based against *Porphyromonas gingivalis*: experimental research. *J Kedokt Gigi Univ Padjadjaran*. 2023 Apr 30;35(1):7.
26. Kabani D, Jaber A, Sater FA, Ibrahim G, Cheble E. Lebanese Propolis from Different Regions: Phytochemical Screening, Antioxidant Activity and Effect against Cancer Cells. *J Apitherapy*. 2022;9(3):1–9.
27. Idris L, Adli MA, Yaacop NN, Mohd Zohdi R. Phytochemical Screening and Antioxidant Activities of *Geniotrigona thoracica* Propolis Extracts Derived from Different Locations in Malaysia. *Malaysian J Fundam Appl Sci*. 2023 Dec 4;19(6):1023–32.
28. Kadkhoda Z, Amarlu Z, Eshraghi S, Samiei N. Antimicrobial effect of chlorhexidine on *Aggregatibacter actinomycetemcomitans* biofilms associated with peri-implantitis. *J Dent Res Dent Clin Dent Prospects*. 2016 Aug 17;10(3):176–80.
29. Gomes KO, Messias da Silva LCF, dos Santos RD, Prado BA, da Silva Montes P, Silva Rodrigues LF, et al. Chemical characterization and antibacterial activities of Brazilian propolis extracts from *Apis mellifera* bees and stingless bees (*Meliponini*). Nalbone L, editor. *PLoS One*. 2024 Jul 16;19(7):e0307289.
30. Herbert BA, Novince CM, Kirkwood KL. *Aggregatibacter actinomycetemcomitans*, a potent immunoregulator of the periodontal host defense system and alveolar bone homeostasis. *Mol Oral Microbiol*. 2016 Jun 22;31(3):207–27.
31. Nugroho N. Uji Efektivitas Antimikroba Ekstrak Propolis *Trigona* sp Terhadap Pertumbuhan Bakteri *Staphylococcus aureus* Secara In-Vitro. Universitas Brawijaya; 2014.
32. Wulandari DT, Supomo S, Warnida H. Uji Aktivitas Antibakteri Ekstrak Metanol Propolis dari Lebah Kelulut (*Heterotrigona itama*) terhadap Bakteri *Pseudomonas aeruginosa* dan *Staphylococcus aureus*. *Biosci J Ilm Biol*. 2023 Dec 30;11(2):1933.
33. Sinaga YMR, Rahayu TI, Perdhana FF, Ariyana MD, Amaro M. Efektivitas Antimikroba Ekstrak Air Propolis *Trigona* spp Asal Lombok. *J Kolaboratif Sains*. 2024;7(6).
34. Hidayat M, Sultan; Saddiah, Siti Halimatu YA. Aktivitas Ekstrak Kasar Propolis *Trigona* spp., terhadap Pertumbuhan Bakteri *Staphylococcus aureus*. *J Pendidik Tambusai*. 2025;9(1):4432–6.
35. Maghfiroh DO. Potensi propolis *Trigona* sp. terhadap jamur penyebab kandidiasis vulvovaginal. *Media Husada J Midwifery Sci*. 2025 Jan 30;3(1):7–12.
36. Tavafi H, Sadrzadeh-Afshar M sadat, Niroomand S. In vitro effectiveness of antimicrobial properties of propolis and chlorhexidine on oral pathogens: A comparative study. *BiosisBiological Syst*. 2020 Oct 15;1(3):116–25.
37. Ellis S. The effect of chlorhexidine mouthwash vs propolis mouthwash on the nitrate-reducing activity of oral bacteria and vascular control in healthy individuals. *Plymouth Student Sci*. 2021;14(1).